The drug fingolimod restores hippocampal synaptic plasticity and improves memory function, and as such, it is commonly used to treat patients with multiple sclerosis. Researchers at the University of Barcelona and the August Pi Sunyer Biomedical Research Institute investigated other applications of the drug; preclinical results show an improvement of cognitive deficits in mice with Huntington’s disease. The first author of the paper points out “Findings constitute a significant step forward in understanding how fingolimod acts on brain cells; it has been proved that it can be an effective drug to treat diseases affecting the hippocampus, like Huntington’s disease and Alzheimer’s disease”. Clinical trials are expected to proceed.
Read the research article here.